health Pfizer and Valneva Report 70% Efficacy for Lyme Disease Vaccine Candidate
Major breakthrough as Pfizer and Valneva announce promising Phase 3 results for PF-07307405, marking a potential first-line defense against Lyme disease with strong safety profiles.
